<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038220</url>
  </required_header>
  <id_info>
    <org_study_id>M00-154</org_study_id>
    <nct_id>NCT00038220</nct_id>
    <nct_alias>NCT00006189</nct_alias>
  </id_info>
  <brief_title>Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients</brief_title>
  <official_title>A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to Completely Suppress Viral Replication in Subjects Infected With HIV-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the&#xD;
      growth of HIV in patients infected with the virus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in each group demonstrating complete suppression of viral replication at Week 144.</measure>
  </primary_outcome>
  <enrollment>40</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir DF</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have HIV Infection.&#xD;
&#xD;
          -  Age 18 to 65 years old.&#xD;
&#xD;
          -  Show no signs of recent illness other than HIV infection.&#xD;
&#xD;
          -  Agree to use a barrier method of birth control during the study and for 30 days after&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are unable to follow study requirements (in the opinion of the investigator).&#xD;
&#xD;
          -  Are pregnant or breast-feeding.&#xD;
&#xD;
          -  Are unable to take medications by mouth.&#xD;
&#xD;
          -  Have chronic nausea or vomiting.&#xD;
&#xD;
          -  Have cancer other than Kaposi's sarcoma or basal cell carcinoma.&#xD;
&#xD;
          -  Have active, serious infections (other than HIV) requiring antibiotic injections&#xD;
             within 15 days prior to screening.&#xD;
&#xD;
          -  Are taking any medications that are not allowed with ABT-378/r and efavirenz.&#xD;
&#xD;
          -  Are taking or have taken any other experimental drugs, antiretroviral drugs, or drugs&#xD;
             that affect the immune system within 30 days of start of study without consent of the&#xD;
             medical monitor.&#xD;
&#xD;
          -  Are receiving or have received radiation therapy within 30 days of start of study&#xD;
             without consent of the medical monitor.&#xD;
&#xD;
          -  Have a history of drug abuse or mental illness that would prevent the patient from&#xD;
             following the protocol requirements.&#xD;
&#xD;
          -  Have a history of kidney or bone disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Brun, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Head, Antiviral Global Project Team</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aaron Diamond AIDS Research Center - Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>May 29, 2002</study_first_submitted>
  <study_first_submitted_qc>May 29, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2002</study_first_posted>
  <last_update_submitted>July 26, 2006</last_update_submitted>
  <last_update_submitted_qc>July 26, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2006</last_update_posted>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

